<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04820959</url>
  </required_header>
  <id_info>
    <org_study_id>BOUCHOT ANR 2017</org_study_id>
    <nct_id>NCT04820959</nct_id>
  </id_info>
  <brief_title>Validation of New Therapeutic Targets to Prevent Collagen Accumulation During Cardiac Fibrosis: Procollagen C-proteinase Enhancers</brief_title>
  <acronym>CARDIACTIV</acronym>
  <official_title>Validation of New Therapeutic Targets to Prevent Collagen Accumulation During Cardiac Fibrosis: Procollagen C-proteinase Enhancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart failure is characterized by cardiac fibrosis linked to extracellular collagen deposits.&#xD;
      Collagens are synthesized as soluble precursors, procollagens, which must undergo proteolytic&#xD;
      maturation to assemble into fibres. This step is under the control of two extracellular&#xD;
      proteins, procollagen C-proteinase enhancer 1 and 2 (PCPE-1 and -2). The mechanism of action&#xD;
      of these highly effective and specific activators was recently elucidated by one of our&#xD;
      partners. Preliminary results, as well as data from the literature, indicate a strong&#xD;
      correlation between the expression rates of PCPEs and cardiac fibrosis. The aim of this study&#xD;
      is to validate in humans, by analysis of endomyocardial tissue biopsies, the hypothesis that&#xD;
      PCPEs contribute to the anarchic accumulation of collagen during cardiac fibrosis and to&#xD;
      evaluate the interest of developing new diagnostic and therapeutic strategies for cardiac&#xD;
      fibrosis using PCPE agonists.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 4, 2020</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial fibrosis rate</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Measurement of the level of myocardial fibrosis in myocardial tissue.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of PCPE-1/2</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Measurement of PCPE-1/2 rate in myocardial tissue.</description>
  </primary_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Valvulopathy</condition>
  <condition>Heart Surgery</condition>
  <condition>Procollagen C-Proteinase Enhancers</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Biopsies</intervention_name>
    <description>Three endomyocardial intraoperative biopsies were performed on the left ventricle.&#xD;
Resection of the left atrium in the event of atrial fibrillation.</description>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Pre-operative blood sampling</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Person who has given written consent&#xD;
&#xD;
          -  Patient aged 18 to 85 for men and 60 to 85 for women&#xD;
&#xD;
          -  Patient requiring cardiac surgery for aortic valve replacement or aortic plastic&#xD;
             surgery or aortic plasty or ascending aorta replacement more or less associated with&#xD;
             aortic valve surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Person not affiliated or not benefiting from national health insurance&#xD;
&#xD;
          -  Person subject to a measure of legal protection (curatorship, guardianship)&#xD;
&#xD;
          -  Person deprived of liberty, by judicial or administrative decision&#xD;
&#xD;
          -  Major incapable or incapable of giving consent&#xD;
&#xD;
          -  Minor&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  Emergency Surgery&#xD;
&#xD;
          -  Acute Infectious Endocarditis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Olivier BOUCHOT</last_name>
    <phone>03.80.29.33.52</phone>
    <phone_ext>+33</phone_ext>
    <email>Olivier.bouchot@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier BOUCHOT</last_name>
      <phone>03.80.29.33.52</phone>
      <phone_ext>+33</phone_ext>
      <email>Olivier.bouchot@chu-dijon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Valve Diseases</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

